Jazz Pharmaceuticals PLC $JAZZ Stock Holdings Boosted by Kovack Advisors Inc.

Kovack Advisors Inc. lifted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 56,485 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,068 shares during the period. Kovack Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $5,994,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of JAZZ. GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 63.7% during the first quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company’s stock worth $126,000 after acquiring an additional 395 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Jazz Pharmaceuticals by 5.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,334 shares of the specialty pharmaceutical company’s stock worth $538,000 after acquiring an additional 232 shares during the last quarter. Spire Wealth Management grew its position in shares of Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 161 shares during the last quarter. Rossby Financial LCC acquired a new stake in Jazz Pharmaceuticals in the first quarter worth about $142,000. Finally, Meritage Portfolio Management grew its position in Jazz Pharmaceuticals by 14.4% in the 1st quarter. Meritage Portfolio Management now owns 75,803 shares of the specialty pharmaceutical company’s stock valued at $9,411,000 after buying an additional 9,529 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $136.30 on Friday. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $8.27 billion, a price-to-earnings ratio of -20.25, a PEG ratio of 8.49 and a beta of 0.28. The firm has a 50-day moving average of $131.90 and a two-hundred day moving average of $117.88.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company posted $5.30 earnings per share. Jazz Pharmaceuticals’s revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the completion of the sale, the director directly owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. This represents a 0.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders have sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on JAZZ shares. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Morgan Stanley set a $183.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, October 24th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Finally, The Goldman Sachs Group increased their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $179.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.